Hormone replacement therapy (HRT) patch shortages in menopause explained
Hormone replacement therapy (HRT) patch are in increasing demand and shortages are driven by a combination of outdated science, disrupted supply chains and misaligned pharmaceutical incentives. Following the misinterpretation of the Women's Health Initiative study in 2002, demand for hormone therapy collapsed, halting innovation for over two decades. Today, demand is rapidly rising again, but supply has not kept pace due to low pricing structures and lack of investment. As a result, many countries now face persistent shortages of HRT patches. The underlying issue is not just supply, but the absence of modern, scalable product innovation.
Connect with Raisa and Johanna on LinkedIn
The need-to-know:
The shortage is not accidental. It is structural. Decades of underinvestment and pricing pressure have made hormone patches commercially unattractive for large pharmaceutical companies.
Demand is accelerating faster than supply can respond. Rising awareness of menopause health and updated clinical guidance are rapidly increasing long-term usage rates.
Innovation has stalled for over 20 years. Current patches are legacy products with known limitations in adhesion, comfort, and reliability.
Let’s go a little further
The conversation with Raisa Monteiro and Johanna Wicks reveals a clear pattern: when markets fail to prioritise human need, innovation stalls. In menopause care, that stall has lasted more than two decades.
At the centre of this issue is a widely misunderstood moment in medical history. The Women's Health Initiative study triggered a global decline in hormone therapy usage. Pharmaceutical companies responded rationally. They redirected capital away from hormone-based products toward higher-margin innovations. The consequence was predictable. No new menopause patches. No material innovation. No system resilience.
Now the cycle has reversed. Awareness has increased. Clinical understanding has improved. Women are re-engaging with hormone therapy not as a short-term intervention, but as a long-term health strategy supporting bone density, cardiovascular health, and quality of life.
The system, however, has not caught up.
As described in the discussion , supply chains are constrained, pricing structures in markets like Australia reduce commercial incentives, and existing products are not designed for modern expectations. This creates a mismatch between demand and capability.
What makes this case particularly instructive for CEOs is not just the market gap. It is the nature of the opportunity.
Raisa Monteiro brings deep expertise in materials science. Her perspective reframes the problem. A patch is not simply a delivery mechanism. It is a materials challenge. Adhesion, skin compatibility, drug stability, and release consistency all depend on design choices that have not meaningfully evolved in 20 years.
This is where insight becomes leverage.
The founders are not attempting incremental improvement. They are approaching the category as a platform. Generation one solves a supply and quality problem. Generation two expands into a broader transdermal delivery system with applications beyond menopause.
This is a pattern worth noting. The most durable companies do not solve a single problem. They solve a class of problems.
There is also a leadership dimension that deserves attention.
Both founders emphasise values alignment over speed. In early-stage companies, the temptation to accept any partnership is strong. Capital, distribution, and manufacturing access can appear urgent. Yet they are deliberately selective. They prioritise partners who are willing to learn, not just transact.
This is a critical distinction.
Partnerships that scale are built on shared understanding, not just shared incentives. The ability to “teach the partner” becomes a strategic advantage. It filters out misalignment early and strengthens execution later.
Equally, their commitment to product integrity is non-negotiable. They are clear that they will not compromise on materials quality for margin. This is not idealism. It is positioning. When the end user is also the founder, shortcuts become visible immediately.
There is a broader implication here for CEOs.
Markets often signal opportunity through inefficiency. Shortages, poor user experience, and outdated products are not isolated problems. They are indicators of neglected categories. The question is not whether the opportunity exists. It is whether you are willing to pursue it with the required depth.
In this case, depth means combining scientific expertise, lived experience, and system-level understanding. It also means accepting that early progress will be constrained by partnerships, regulation, and capital.
The founders are clear on their trajectory. In one year, they aim to complete product development. In three years, they expect to be in market. This is not speculative ambition. It is structured execution based on known regulatory pathways.
For CEOs, the lesson is straightforward.
Innovation does not always require new science. Often, it requires revisiting neglected problems with modern capability and disciplined focus.
The menopause care market is expanding rapidly. Yet the real story is not growth. It is correction. A system that ignored a critical need is now being rebuilt.
The question is who will lead that rebuild.
Question for you
If your market is showing clear signs of neglect, are you prepared to build the capability required to lead its reinvention—and who would you need to partner with to do it well?
When you're ready, there are two ways I can help you:
1. CEO Coaching: For CEOs and soon-to-be CEOs who want to lead with clarity and grow their business without sacrificing what matters most. A tailored 12-session experience with three interconnected elements: scaling you as a leader, elevating how you lead others, and creating conditions for sustainable business growth.
2. Leadership Events: What if your leaders left the room thinking differently about ambition and their role in achieving it? I've worked with military special operations leaders and leadership teams at Cochlear and Lifeblood where poor leadership costs lives. Looking for real stories, frameworks and insights that shift how leaders think about ambition, create leverage and build teams worth following? Book me for your next conference, offsite, or leadership event.
Looking for something different? Send me an email.
